BeOne Medicines Ltd. (ONC) operating KPIs
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$370.33−1.23 (-0.33%)
Close on Oct 30, 2026Market cap $42.11BP/E 66.2Yield –
BeOne Medicines accrued Sales Rebates & Returns Reserve — Ending Balance ($M) ($M)
Form 10-Q / 10-K Accrued Sales Rebates Rollforward Note (XBRL)
Latest, Q2 2026
486
Period ended Jun 30, 2026
Change on a year earlier
+63.4%
297 in Q2 2025
History
36 quarters
Since Q4 2016
Sources
30
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Accrued Sales Rebates & Returns Reserve — Ending Balance ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 486 | +63.4% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 440 | +69.4% | Form 10-Q (filed 2026-05-06) ↗ |
| Q4 2025 | Dec 31, 2025 | 399 | +69.1% | Form 10-Q (filed 2026-08-05) ↗ |
| Q3 2025 | Sep 30, 2025 | 383 | +79.0% | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2025 | Jun 30, 2025 | 297 | +71.6% | Form 10-Q (filed 2025-08-06) ↗ |
| Q1 2025 | Mar 31, 2025 | 260 | +39.5% | Form 10-Q (filed 2025-05-07) ↗ |
| Q4 2024 | Dec 31, 2024 | 236 | +68.4% | Form 10-K (filed 2026-02-26) ↗ |
| Q3 2024 | Sep 30, 2024 | 214 | +90.4% | Form 10-Q (filed 2024-11-12) ↗ |
| Q2 2024 | Jun 30, 2024 | 173 | +102.5% | Form 10-Q (filed 2024-08-07) ↗ |
| Q1 2024 | Mar 31, 2024 | 186 | +136.7% | Form 10-Q (filed 2024-05-08) ↗ |
| Q4 2023 | Dec 31, 2023 | 140 | +234.7% | Form 10-K (filed 2025-02-27) ↗ |
| Q3 2023 | Sep 30, 2023 | 112 | +125.1% | Form 10-Q (filed 2024-11-12) ↗ |
| Q2 2023 | Jun 30, 2023 | 85.6 | +19.7% | Form 10-Q (filed 2024-08-07) ↗ |
| Q1 2023 | Mar 31, 2023 | 78.7 | +32.0% | Form 10-Q (filed 2024-05-08) ↗ |
| Q4 2022 | Dec 31, 2022 | 41.8 | -29.9% | Form 10-Q (filed 2024-11-12) ↗ |
| Q3 2022 | Sep 30, 2022 | 49.9 | +147.0% | Form 10-Q (filed 2023-11-09) ↗ |
| Q2 2022 | Jun 30, 2022 | 71.5 | +179.3% | Form 10-Q (filed 2023-08-02) ↗ |
| Q1 2022 | Mar 31, 2022 | 59.6 | +30.4% | Form 10-Q (filed 2023-08-02) ↗ |
| Q4 2021 | Dec 31, 2021 | 59.6 | +400.8% | Form 10-K (filed 2024-02-26) ↗ |
| Q3 2021 | Sep 30, 2021 | 20.2 | +169.3% | Form 10-Q (filed 2022-11-09) ↗ |
| Q2 2021 | Jun 30, 2021 | 25.6 | +556.4% | Form 10-Q (filed 2022-08-08) ↗ |
| Q1 2021 | Mar 31, 2021 | 45.7 | +1,042.5% | Form 10-Q (filed 2022-05-09) ↗ |
| Q4 2020 | Dec 31, 2020 | 11.9 | +271.9% | Form 10-K (filed 2023-02-27) ↗ |
| Q3 2020 | Sep 30, 2020 | 7.50 | +97.4% | Form 10-Q (filed 2021-11-04) ↗ |
| Q2 2020 | Jun 30, 2020 | 3.90 | +44.4% | Form 10-Q (filed 2021-08-05) ↗ |
| Q1 2020 | Mar 31, 2020 | 4 | +17.6% | Form 10-Q (filed 2021-05-06) ↗ |
| Q4 2019 | Dec 31, 2019 | 3.20 | -33.3% | Form 10-K (filed 2022-02-28) ↗ |
| Q3 2019 | Sep 30, 2019 | 3.80 | -7.3% | Form 10-Q (filed 2020-11-05) ↗ |
| Q2 2019 | Jun 30, 2019 | 2.70 | +285.7% | Form 10-Q (filed 2020-08-06) ↗ |
| Q1 2019 | Mar 31, 2019 | 3.40 | -19.0% | Form 10-Q (filed 2019-05-09) ↗ |
| Q4 2018 | Dec 31, 2018 | 4.80 | +20.0% | Form 10-K (filed 2021-02-25) ↗ |
| Q3 2018 | Sep 30, 2018 | 4.10 | – | Form 10-Q (filed 2018-11-08) ↗ |
| Q2 2018 | Jun 30, 2018 | 0.70 | – | Form 10-Q (filed 2018-08-09) ↗ |
| Q1 2018 | Mar 31, 2018 | 4.20 | – | Form 10-Q (filed 2018-05-09) ↗ |
| Q4 2017 | Dec 31, 2017 | 4 | – | Form 10-K (filed 2020-03-02) ↗ |
| Q4 2016 | Dec 31, 2016 | 0 | – | Form 10-K (filed 2019-02-28) ↗ |
Breakdown
What makes up accrued sales rebates & returns reserve — ending balance ($m)
Cite this data
StockData. (2026). BeOne Medicines Accrued Sales Rebates & Returns Reserve — Ending Balance ($M) ($M), quarterly Q4 2016–Q2 2026 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/gtn_reserve_ending
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.